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Endovascular aneurysm sealing (EVAS) using the Nellix device 
(Endologix Inc, Irvine, CA, USA) has been recently introduced 
for the treatment of abdominal aortic aneurysm (AAA), with 
promising results.1,2 The different concept of EVAS seems to 
expand the possibilities of endovascular treatment of aortic 
aneurysm disease and reduce the risk of type II endoleaks after 
treatment.1 Two clinical trials and one investigational device 
exemption (IDE) pivotal trial have been published1–3 to test the 
efficacy and safety of the Nellix device. Since these studies 
were designed as first in human or as IDE trials, selected 
patients were enrolled. More recent data regarding the outcome 
of the Nellix device in everyday clinical practice have been 
reported in 2 multicenter and 3 single-center studies,4–8 all 
reporting a rather low incidence of type I and II endoleak 
(2%–8%) and a high clinical success rate (98%–100%), even in 
ruptured AAAs.8 However, all reports have a short (<12 
months) mean follow-up, and data on midterm outcome are still 
scarce. As the real-world use of this new device is expanding 
rapidly, we report the midterm outcome of a group of patients 
with >12 months’ follow-up treated at 2 vascular centers.
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Abstract
Purpose: To report midterm outcomes of the Nellix Endovascular Aneurysm Sealing (EVAS) System in the treatment 
of abdominal aortic aneurysm (AAA). Methods: Between September 2013 and July 2014, 64 AAA patients (mean 
age 76.6±6.8 years; 61 men) were treated with the EVAS system at 2 centers (only procedures performed at least 
12 months prior to the analysis were included). Most patients were treated for a stable AAA, while 1 patient was 
treated for a ruptured aneurysm. Mean aneurysm diameter was 57.3±9.3 mm. The proximal neck measured a 
mean 21.5±3.3 mm in diameter and 27.0±12.1 mm long; the neck angle was 16.9°±19.3°. Eleven (17.2%) patients 
were treated outside the instructions for use (IFU). Results: Technical success was achieved in 63 (98.4%) of 64 
patients; 1 type Ia endoleak was treated intraoperatively. One (1.6%) aneurysm-related death occurred at 4 months 
due to a secondary aortoenteric fistula. Overall, endoleaks occurred in 3 (4.7%) patients (2 type Ia, 1 type II). The 
estimated rates for 18-month overall survival, freedom from aneurysm-related death, and freedom from secondary 
interventions were 92.7%, 98.4%, and 95.0%, respectively. Patients treated outside the IFU had a significantly higher 
incidence of device-related complications (p=0.03). Conclusion: The use of the Nellix device in everyday clinical 
practice is safe and offers promising midterm results. The risk of secondary aortoenteric fistula requires further 
analysis. Longer follow-up is needed to assess the actual efficacy of the device, although the risk of migration with 
late endoleak seems low.
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Methods
Study Design
Data on all patients treated with the Nellix device at 2 par-
ticipating centers between September 2013 and July 2014 
were retrospectively analyzed based on the intention-to-
treat principle; only procedures performed at least 12 
months prior to the analysis were included. Patients were 
eligible for endovascular repair with an infrarenal AAA >5 
cm in axial diameter or with rapid growth (>1 cm in the last 
12 months). The instructions for use (IFU) list the appropri-
ate anatomy for the Nellix device as a nonaneurysmal aortic 
neck ≥10 mm long with a diameter between 18 and 32 mm, 
a maximum aortic blood flow lumen diameter ≤60 mm, a 
maximum common iliac artery (CIA) diameter between 9 
and 35 mm, and a <60° angle from neck to sac, but these 
were not considered strict inclusion criteria. At the begin-
ning of the EVAS experience at both centers, patients were 
considered for EVAS if their anatomy complied with the 
IFU and they were older than average AAA patients. The 
decision to treat older patients with shorter life expectancy 
was based on the lack of data on the long-term performance 
of the device. Later, after the learning curve, patients not 
complying with the IFU were also included according to the 
treating physician’s decision.
Follow-up visits were completed according to each cen-
ter’s internal policy. Minimal follow-up was a clinical 
examination (with duplex imaging) at 30 days and com-
puted tomography angiography (CTA) at 3 months after the 
procedure in both centers. Thereafter, 1 center used duplex 
and the other used CTA surveillance imaging at 6 and 12 
months unless endoleaks or other problems warranted an 
accelerated schedule. All patients were given a full explana-
tion of the procedure and signed a consent form with autho-
rization to release anonymized data.
EVAS Procedure
The Nellix device and the EVAS procedure have been 
described in previous publications.1,2 In brief, femoral 
access was obtained either percutaneously or with surgical 
exposure, according to the operator’s preference. 
Intraoperative aortography was performed to identify the 
renal arteries and then access wires were exchanged for a 
0.035-inch extra-stiff wire [Lunderquist (Cook Medical Inc, 
Bloomington, IN, USA) or Backup Meier (Boston 
Scientific, Marlborough, MA, USA)]. The 2 components of 
the Nellix system were inserted and the endoframes were 
expanded. Contrast-enhanced saline was injected in the 
endobags under fluoroscopic guidance to determine the vol-
ume required to fill the aneurysm sac. The endobags were 
then filled with polymer, with a mean fill pressure ~50 mm 
Hg higher than the patient’s systolic pressure, not exceeding 
200 mm Hg. Secondary fills were performed when 
necessary. The delivery catheters were then released from 
the implant and removed after the polymer had cured.
Patient Population
During the observation period, 64 patients (mean age 76.6±6.8 
years; 61 men) were treated with the EVAS system (1 with a 
ruptured aneurysm). Mean aneurysm diameter was 57.3±9.3 
mm, with a mean blood lumen diameter of 37.8±10.1 mm. 
Mean proximal neck diameter was 21.5±3.3 mm, with a mean 
neck length of 27.0±12.1 mm; the neck angle was 16.9°±19.3°. 
CIA diameter was 13.9±3.7 mm. Eleven (17.2%) patients 
were treated outside the current IFU. Patient demographics 
and aneurysm characteristics are given in Table 1.
Outcome Measures
Outcomes are reported according to the reporting standards 
for endovascular aortic aneurysm repair.9 Technical success 
was defined as the successful deployment of the device in the 
Table 1. Demographic Variables and Aneurysm Characteristics 






Smoking habit 38 (59.4)
Chronic kidney diseaseb 8 (12.5)
History of AMI 16 (25)
Peripheral artery disease 7 (10.9)
CAD 19 (29.7)
COPD 29 (45.3)
ASA II 39 (60.9)
ASA III/IV 24 (37.5)
ASA V 1 (1.6)
Aneurysm diameter, mm 56.4±11.3
Blood lumen diameter, mm 37.7±10.2
Proximal neck diameter, mm 21.5±3.3
Neck length, mm 27.0±12.1
Neck angle, deg 16.9±19.5
CIA diameter, mm 13.9±3.7
Patients outside of the IFU 11 (17.2)
 Aortic neck angle >60° 3
 Aortic neck <10 mm 3
 Aortic neck diameter <18 mm 4
 CIA diameter <8 mm 1
Abbreviations: AMI, acute myocardial infarction; ASA, American Society 
of Anesthesiologists; CAD, coronary artery disease; CIA, common iliac 
artery; COPD: chronic obstructive pulmonary disease; IFU, instructions 
for use.
aContinuous data are presented as the means ± standard deviation; 
categorical data are given as the counts (percentage).
bDefined as serum creatinine >1.5 mg/dL.
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planned position with aneurysm sealing and no type I 
endoleak or stent thrombosis. Assisted primary technical suc-
cess referred to the unplanned use of endovascular proce-
dures as necessary, such as balloons other than those of the 
device or the insertion of stents to address endoleak. Clinical 
success was defined as successful deployment of the device 
at the intended location without major adverse events 
(MAEs), type I endoleak, graft infection or thrombosis, aneu-
rysm expansion or rupture, and conversion to open repair. 
Major adverse events included all-cause mortality, bowel 
ischemia, myocardial infarction (MI), renal failure (requiring 
dialysis or elevated serum creatinine 2 times baseline), respi-
ratory failure (need for >24 hour mechanical ventilation post-
operatively or reintubation for any reason), and stroke.
Statistical Analysis
Results are presented as mean ± standard deviation or 
median and absolute range, as appropriate. Comparison of 
categorical data was performed using the Fisher exact test. 
Kaplan-Meier estimates of overall mortality, freedom from 
aneurysm-related mortality, and freedom from secondary 
procedures are expressed with the 95% confidence interval 
(CI). The incidence of device-related complications was 
compared between patients treated within vs outside the 
IFU; results are reported as the odds ratio (OR) and 95% CI. 
Statistical significance was indicated by a 2-tailed p<0.05. 
GraphPad Prism (version 6; GraphPad Software, La Jolla, 
CA, USA) was used for data analyses.
Results
Procedure Outcomes
Technical success was achieved in 63 (98.4%) patients; 1 
intraoperative type Ia endoleak was detected at completion 
angiography and treated (100% assisted primary technical 
success). The procedure was performed under general (40, 
62.5%) or local anesthesia (24, 37.5%) according to opera-
tor preference. The mean procedure time was 97.9±29.6 
minutes (range 56–182), during which 117±66.1 mL of con-
trast were used for fluoroscopy (mean 8±2 minutes). The 
mean intraoperative blood loss was 201±138 mL. A mean 
74.5±27 mL of polymer was delivered at a mean inflation 
pressure of 186±15 mm Hg. In one case a concomitant 
hypogastric aneurysm was treated without complications. 
No patients required intensive care. Mean hospital stay 
from the date of the procedure was 3.3±4.6 days (range 
1–35, median 2). Procedure data are shown in Table 2.
Clinical Outcomes
There were no perioperative major adverse events or other 
major complications at 30 days. Minor complications 
included 3 (4.7%) cases of postoperative fever and 3 access 
complications (inguinal hematoma, dehiscence of the ingui-
nal cutdown) not requiring surgical treatment.
Including the intraoperative type Ia endoleak, there were 
3 (4.7%) endoleaks encountered during the observation 
period. Another type Ia endoleak was detected and cor-
rected at 15 months from the index operation. Both the type 
I endoleaks occurred in cases treated outside the current 
IFU. The intraoperative leak was due to an 80° proximal 
neck angulation in an 18-mm-diameter, 10-mm-long neck; 
the second was due to a small neck diameter (17 mm, 11 
mm in length). Both patients were successfully treated with 
the deployment two 12×41-mm Advanta V12 (Maquet 
Getinge Group, Göteborg, Sweden) covered stents in the 
first and two 11×15-mm Viabahn covered stents (W. L. 
Gore & Associates, Flagstaff, AZ, USA) in the second. The 
only type II endoleak, detected at 3-month CTA control, is 
under surveillance, without aneurysm growth.
At 2 months, 1 (1.6%) patient was diagnosed with throm-
bosis of the external iliac artery (EIA) distal to the landing 
zone of the device, which remained patent. This patient 
underwent surgical embolectomy, complicated by distal 
embolization, with complete recovery and without further 
adverse events during follow-up.
Median follow-up for the group was 17 months (abso-
lute range 2–22). All patients had at least 1 follow-up CTA 
within the first 3 months after the procedure. Aneurysm-
related mortality was 1.6%. One patient was treated for a 
secondary aortoduodenal fistula (ADF) occurring 4 
months after EVAS, resulting in death on the 24th postop-
erative day. This patient was treated outside the IFU 
(proximal neck angle 70°). The overall mortality was 
6.2%. Besides the aforementioned case, the 3 additional 
deaths were all considered unrelated to the aneurysm. One 
patient died at 6 months due to acute pancreatitis, another 
at 16 months due to respiratory failure secondary to pul-
monary infection, and the third died at 2 months due to 
acute MI. All these patients had at least 1 CTA showing 
complete exclusion of the aneurysm, without endoleak.
Table 2. Variables in the 64 EVAS Procedures.a
Procedure time, min 97.9±29.6
Fluoroscopy time, min 8±2
Local anesthesia 24 (37.5)
Contrast volume, mL 117±66.1
Blood loss, mL 201±138
Volume of polymer, mL 69.5±27
Hospital LOS, d 3.3±4.6
Percutaneous procedures 46 (71.8)
Intraoperative endoleaks 1 (1.6)
Unplanned procedures 1 (1.6)
Abbreviations: EVAS, endovascular aneurysm sealing; LOS, length of stay.
aContinuous data are presented as the means ± standard deviation; 
categorical data are given as the counts (percentage).
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There have been no aneurysm ruptures, no device migra-
tion, and no aneurysm enlargement. The Kaplan-Meier esti-
mate for overall survival at 18 months was 92.7% (95% CI 
81.2 to 97.2), while freedom from aneurysm-related death 
was 98.4% (95% CI 89.3 to 99.8), with the 1 device-related 
death. The estimate for freedom from reintervention was 
95.0% (95% CI 85.3 to 98.3), with 1 type Ia endoleak, 1 
EIA occlusion, and 1 case ADF (Figure 1).
Aneurysm diameter reduction or increase >5 mm was 
not detected in any patient. Patients treated outside the IFU 
had a significantly higher incidence of device-related com-
plications (OR 9.6, 95% CI 1.38 to 66.5, p=0.03) owing to 
1 ADF and 2 type Ia endoleaks vs 1 type II endoleak and 1 
EIA thrombosis in the IFU-compliant patients.
Discussion
Our study reports the midterm results of a group of patients 
treated with the Nellix device in a real world setting. Our 
30-day results are in line with those reported by other 
groups1,5–8 and seem to confirm that EVAS is a safe and 
effective procedure, with a low incidence of perioperative 
MAEs, a short procedure time, and no intraoperative deaths. 
Our not negligible overall mortality (6.2%) is in our opinion 
related mostly to the older age of the study group, with 3 of 
the 4 deaths unrelated to the aneurysm or procedure.
We experienced only 1 type II endoleak, an incidence 
that is in line with other studies.1,5–8 It is believed that type 
II endoleaks in EVAS are caused by inadequate unfurling of 
the endobags,10 which are therefore unable to reach and seal 
the lumbar arteries. In our case, we actually detected a 
severely calcified plaque encompassing the ostia of the 
lumbar arteries feeding the endoleak. Although this consid-
eration remains speculative, the plaque might have pre-
vented optimal apposition of the bag to the aortic wall.
Treatment of type Ia endoleak after EVAS has usually 
been achieved with direct embolization,11 while spontane-
ous resolution has also been reported.5 Both patients with 
type Ia endoleak had a small proximal neck, with tight 
angulation in 1 case. Treatment with covered stents aimed 
to improve apposition of the Nellix stents and endobags 
against the aortic wall and to occupy a greater portion of the 
transverse area of the proximal neck. The goal was there-
fore to divert more flow into the Nellix stents, hoping that 
the remaining flow would be slow enough to obtain 
thrombosis.
Harvey et al11 also had similar ideas regarding the role of 
proximal extensions to change the flow pattern of type Ia 
endoleaks. The authors described a technique for type Ia 
endoleak based on n-butyl cyanoacrylate embolization 
associated with proximal extension of the Nellix stent 
lumen with covered stents, reporting that the use of covered 
stents actually changed the flow pattern of type Ia endo-
leaks from high-velocity flow to a low-flow situation. In 
our 2 cases, the change in flow pattern was enough to 
resolve the endoleaks, although we still consider direct 
embolization in case of recurrence (both patients are under 
close clinical surveillance).
As previously stated, both type Ia endoleaks occurred in 
patients with suboptimal proximal necks, either for angula-
tion and/or diameter. As reported by other authors,4,6 we 
also believe that factors such as proximal neck angulation, 
stomach-shaped aneurysms, and large blood lumens should 
be thoroughly evaluated when planning an EVAS proce-
dure. Due to the stiffness of the system, these features seem 
to favor migration of the Nellix stents during inflation of the 
Figure 1. Kaplan-Meier analyses of (A) overall survival,  
(B) freedom from aneurysm-related death, and (C) freedom 
from reintervention. SE, standard error.
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endobags, leading to a more distal deployment than origi-
nally intended with the risk of type Ia endoleaks. Brownrigg 
et al6 suggest keeping the Nellix balloons inflated during 
polymer injection to stabilize the system and minimize this 
risk, although the actual efficacy of this technique is yet to 
be proven.
No type Ib endoleak occurred although 1 patient suffered 
from EIA occlusion. The reported incidence of device or 
iliac artery stenosis/occlusion has a variable incidence, 
ranging between 2% and 8%.5–7 These events can be related 
to the fact that the Nellix is a low-profile device, and if 
patients with small and calcified iliac arteries are treated, 
the risk of access complications may be increased. 
Consistent with these considerations, a not negligible rate 
of limb stenosis/occlusion has also been reported with other 
ultra-low profile devices.12
A second and more specific cause of limb occlusion is 
the straightening of the aortoiliac anatomy caused by the 
stiffness of the Nellix graft. This straightening causes the 
displacement of angulations from inside to outside the dis-
tal end of the graft,7,10 meaning that, in a tortuous distal 
landing zone, all curves become more heightened in the 
arterial segments that are free from the device, with possi-
ble misalignments or kinks. Although no striking misalign-
ment was evident at completion angiography in the patient 
who suffered from EIA thrombosis, we actually believe that 
distal landing zone tortuosity, associated with poor compli-
ance with the recommended antiplatelet therapy, might 
have played a role in the development of this event. The use 
of adjunctive self-expanding stents is suggested to reduce 
and modulate the tightness of eventual distal bends,6,10 
although its efficacy was not proven in the large multicenter 
registry by Böckler et al.5
The most important device-related complication in our 
study was an ADF 4 months after implant.13 Only one other 
case of secondary ADF has been recently reported in the lit-
erature, also 4 months after the procedure.14 Although the 
possible mechanism of fistula formation remains specula-
tive, erosion of the stiff polymer-filled endobags into the 
aortic wall and then into the duodenum cannot be excluded. 
The early occurrence (4 months) of both cases is, however, 
peculiar. Secondary aortoenteric fistulas are known to be 
time-dependent, with a higher incidence late in follow-up. 
Both reported cases instead occurred within the first 12 
months from the procedure, and no other has been so far 
reported. On the other hand, this short interval is also com-
patible with a primary infection of the endograft, leading to 
aortic rupture and fistula formation.13,14 In this event, the 
ADF would be only a consequence of graft infection and not 
the initial cause. This second hypothesis might be supported 
by another early infection case (at 8 months) described by 
Tolenaar et al,14 which caused aortic rupture (without fistula 
formation). Ferrero et al13 also suggested that aortic throm-
bus may protect against secondary ADF, with patients 
having less thrombus being at greater risk. Further evidence 
is needed to evaluate the actual incidence of this complica-
tion and the factors that might favor this event.
An interesting aspect of our study is that all but one com-
plication occurred within 6 months after implant. One pos-
sible explanation, as also pointed out by other authors,10 is 
that the device tends to stabilize the AAA anatomy, mean-
ing that a device-related complication has to occur early as 
the aorta-device geometry will not change over time. 
Consistent with this eventuality, we detected only 1 late 
type Ia endoleak (at 15 months), supporting a low tendency 
to migration of the device, at least in the midterm.
Patients treated outside the IFU in our cohort had a statis-
tically higher incidence of device-related complications. This 
is in contrast with the results of the largest multicenter regis-
try of EVAS procedures, where Böckler et al5 did not find a 
higher frequency of type Ia or Ib endoleak, device occlusion, 
or reintervention in patients treated outside the IFU.
Although the list of anatomical requirements for EVAS 
includes several parameters, we believe that proximal neck 
features (angulation and small diameter) remain among the 
most stringent, as all the most important complications of 
the present study occurred in this subgroup of patients. This 
same outcome has also been reported by other authors.4,6 
Böckler et al5 performed no specific analysis in this regard 
as all patients not complying with the IFU were analyzed 
together. Future analyses should be directed to better char-
acterizing the role of the proximal neck as a predictor of 
failure.
Conclusion
The use of the Nellix device in everyday clinical practice is 
safe and offers promising midterm results. The low number 
of endoleaks and the stabilization of the aneurysm seem to 
provide a durable solution, with a low incidence of reinter-
ventions. Caution should be used in the setting of small, 
angulated proximal necks, as they seem to be associated 
with a higher risk of complications. Longer follow-up is 
awaited to assess the actual efficacy of the device.
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